Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia

Hussain A Al-Omar,Hind S Almodaimegh,Abubker Omaer,Lamya M Alzubaidi,Bandar Al-Harbi,Ibtisam Al-Harbi,Mohamed Hassan,Abdulmohsen Abanumay,Omar Akhtar,Hussain A. Al-Omar,Hind S. Almodaimegh,Lamya M. Alzubaidi

DOI: https://doi.org/10.1080/13696998.2024.2319458

2024-03-13

Journal of Medical Economics

Abstract:Background and Objectives This study presents a budget impact analysis (BIA) conducted in Saudi Arabia, evaluating the cost implications of adopting semaglutide, tirzepatide, or dulaglutide in the management of type 2 diabetes mellitus (T2DM) patients. The analysis aims to assess the individual budgetary impact of these treatment options on healthcare budgets and provide insights for decision-makers.

medicine, general & internal,health care sciences & services

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the budgetary impact of three glucagon - like peptide - 1 receptor agonists (GLP - 1 RA) - semaglutide, tirzepatide and dulaglutide for the management of type 2 diabetes mellitus (T2DM) in Saudi Arabia. Specifically, the study aims to:

1. **Evaluate budgetary impact**: Through a 5 - year budget impact analysis (BIA), evaluate the specific financial impact of these three drugs on the budget of the Saudi Arabian public healthcare system.

2. **Compare the cost - effectiveness of different treatment regimens**: Analyze the clinical effects of each drug in terms of HbA1c control, weight loss, reduction of cardiovascular events, etc., and their corresponding cost savings.

3. **Provide a basis for decision - making**: Provide information on the potential financial impact of these drugs to healthcare policymakers, payers and healthcare providers in Saudi Arabia, helping them make more informed resource allocation decisions.

### Research background
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease, and its incidence is increasing year by year globally, especially in Gulf countries such as Saudi Arabia. T2DM not only increases the risk of microvascular and macrovascular complications, but also leads to a huge economic burden. Therefore, effective T2DM management strategies are crucial. GLP - 1 receptor agonists have become an important option for T2DM management because of their advantages in blood - glucose control, weight management and reduction of cardiovascular risk.

### Research methods
The study adopted a prevalence - based budget impact analysis model, combined with real - world data and clinical trial data, and considered the following factors:
- **Disease epidemiology**: Including the total number of T2DM patients, prevalence, mortality, etc.
- **Drug prices**: Price differences among different GLP - 1 RA.
- **Diabetes management costs**: Utilization and costs of medical resources related to T2DM.
- **Costs of cardiovascular complications**: Costs of cardiovascular events (such as non - fatal stroke, myocardial infarction).
- **Savings from weight loss**: The impact of weight loss on other complications (such as chronic kidney disease, hypertension) and the corresponding cost savings.

### Main results
Within a 5 - year time frame, the cumulative budget impacts of semaglutide, tirzepatide and dulaglutide were $85,923,089, $169,790,195 and $94,558,356 respectively. Specifically:
- **Semaglutide**: Showed the lowest incidence of major adverse cardiovascular events (3P - MACE) in the public sector.
- **Tirzepatide**: Performed best in terms of weight loss and HbA1c reduction.
- **Dulaglutide**: Had the highest incidence of 3P - MACE and the worst performance in terms of HbA1c and weight improvement.

### Conclusions
Considerations of cardiovascular cost savings and drug procurement costs may make semaglutide a favorable choice for budget planners and decision - makers in Saudi Arabia. The study results indicate that semaglutide has a high cost - effectiveness under the current evidence, while tirzepatide needs to reduce its price to achieve a budget balance with semaglutide.

Through this study, decision - makers in Saudi Arabia can better understand the potential financial impacts of these three GLP - 1 RA and optimize resource allocation accordingly to improve the efficiency and effectiveness of T2DM management.